NASDAQ:GERN

Geron Stock Insider Trading

Healthcare > Biotechnology

Buy GERN

*Your capital is at risk

$1.16

-0.0100 (-0.85%)

At Close: Jun 03, 2026

Geron Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 89.02. In total, the insiders bought 58.31M and sold 1.36M GERN shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	89.02
● Buy	58.31M shares
● Sell	1.36M shares
97% Buy Activity Strong Negative Correlation
Buy Signal High Confidence May 26, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 89.02. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (97% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 31, 2024 Buy	Common Stock A-Award	Spiegel Robert J. Director	Director	2 206 Value: $8K
Dec 31, 2024 Buy	Common Stock A-Award	Spiegel Robert J. Director	Director	2 206 Value: $8K
Dec 31, 2024 Buy	Common Stock A-Award	Spiegel Robert J. Director	Director	2 206 Value: $8K
Nov 11, 2024 Buy	Common Stock J-Other	Eid Joseph Insider	Other	0 Value: $0
Nov 11, 2024 Buy	Stock Option (right to buy) A-Award	Eid Joseph EVP, Research And Development	Officer	2 500 000 Value: $10.3M
Nov 11, 2024 Buy	Stock Option (right to buy) A-Award	Eid Joseph EVP, Research And Development	Officer	2 500 000 Value: $10.3M
Nov 11, 2024 Buy	Common Stock J-Other	Eid Joseph Insider	Other	0 Value: $0
Sep 30, 2024 Buy	Common Stock A-Award	Spiegel Robert J. Director	Director	1 767 Value: $8K
Sep 30, 2024 Buy	Common Stock A-Award	Spiegel Robert J. Director	Director	1 767 Value: $8K
Sep 30, 2024 Buy	Common Stock A-Award	Spiegel Robert J. Director	Director	1 767 Value: $8K
Sep 30, 2024 Buy	Common Stock A-Award	Spiegel Robert J. Director	Director	1 767 Value: $8K
Sep 09, 2024 Buy	Common Stock J-Other	Ziegler James Insider	Other	0 Value: $0
Sep 09, 2024 Buy	Stock Option (right to buy) A-Award	Ziegler James EVP, Chief Commercial Officer	Officer	1 600 000 Value: $7.06M
Sep 09, 2024 Buy	Stock Option (right to buy) A-Award	Ziegler James EVP, Chief Commercial Officer	Officer	1 600 000 Value: $7.06M
Sep 09, 2024 Buy	Common Stock J-Other	Ziegler James Insider	Other	0 Value: $0
Jul 08, 2024 Buy	Common Stock M-Exempt	Grethlein Andrew J EVP, Chief Operating Officer	C-Suite Officer	674 348 Value: $1.16M
Jul 08, 2024 Buy	Stock Option (right to buy) M-Exempt	Grethlein Andrew J EVP, Chief Operating Officer	C-Suite Officer	452 804 Value: $778.8K
Jul 08, 2024 Sell	Common Stock S-Sale	Grethlein Andrew J EVP, Chief Operating Officer	C-Suite Officer	674 348 Value: $3.07M
Jul 08, 2024 Sell	Common Stock S-Sale	Grethlein Andrew J EVP, Chief Operating Officer	C-Suite Officer	674 348 Value: $3.07M
Jul 08, 2024 Buy	Stock Option (right to buy) M-Exempt	Grethlein Andrew J EVP, Chief Operating Officer	C-Suite Officer	452 804 Value: $778.8K
Jul 08, 2024 Buy	Common Stock M-Exempt	Grethlein Andrew J EVP, Chief Operating Officer	C-Suite Officer	674 348 Value: $1.16M
Jun 28, 2024 Buy	Common Stock A-Award	Spiegel Robert J. Director	Director	1 916 Value: $8K
Jun 28, 2024 Buy	Common Stock A-Award	Spiegel Robert J. Director	Director	1 916 Value: $8K
Mar 29, 2024 Buy	Common Stock A-Award	Spiegel Robert J. Director	Director	2 462 Value: $8K
Mar 29, 2024 Buy	Common Stock A-Award	Spiegel Robert J. Director	Director	2 462 Value: $8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT GERON CORPORATION

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes a...

Read Full Profile Here